Clinical Trial Update: Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing once-weekly semaglutide to exenatide ER 2.0 mg as add-on therapy in adults with type 2 diabetes; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• exenatide ER (exenatide extended-release)
• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2018-03-30